

The Reflection of Hepatitis B Virus Genotyping on Histopathological Pattern and Clinical Presentation Among Egyptian Patients with Chronic Hepatitis B Infection

Thesis

Submitted for the partial fulfillment
of M.D. Degree in Tropical Medicine

By

Sahar Zaghloul Mohammad Maklad

M.B., B.Ch. & M. Sc.

Supervised by

Dr. Ahmad Abd-El-Latif Abou Madyan

Professor of Tropical Medicine

Faculty of Medicine - Cairo University

Dr. Mohamed Abdel Hamid Ahmed

Professor of Microbiology

Faculty of Medicine - Minia University

Dr. Hassan Ahmed Ali El-Garem

Ass. Professor of Tropical Medicine

Faculty of Medicine - Cairo University

Cairo University

2006

Acknowledgement

I was honoured to have ***Dr. Ahmed Abd-El-Latif Abou Madiyan, Prof. of Tropical Medicine, Cairo University*** as my supervisor. His great ideas, encouragement and advice were invaluable. His unlimited fatherly support and indispensable directions gave me a great spirit to carry on.

I would like to express my sincere thanks to ***Dr. Mohamed Abdel Hamid Ahmed, Head and Professor of Microbiology Dep, Minia University*** who was mainly responsible for all the laboratory part of this study. His support, guidance and continuous help were of great importance. He freely gave time and encouragement which enabled me to finish this work.

I would like to express my utmost thanks to ***Dr. Hassan Ahmed Ali El-Garem, Assistant Professor of Tropical Medicine, Cairo University*** for the priceless help and support that he gave. He spent his valuable time and effort reviewing all the work and providing me with endless precious ideas.

I can find no words to thank ***Dr. Soheir Ismail, Consultant of, Hepatology and Tropical Medicine at National Hepatology and Tropical Medicine Research Institute, Cairo*** for her valuable and precious help in the data collection of this research. She gave a lot of time and support to solve problems and conduct the clinical part of this work.

My deepest appreciation to the ***Pathology Department*** at the ***National Hepatology and Tropical Medicine Research Institute*** and the ***Laboratory Staff at HCP Project*** who were very cooperative and helpful although the work.

List of contents

Introduction	1
Aim of work.....	4
Literature Review.....	5
Epidemiology.....	5
Spotlights on the Egyptian situation of HBV.....	14
Virology.....	18
Genotyping.....	30
Immunopathogenesis.....	58
Diagnosis.....	81
Treatment.....	98
Patients & Methods.....	122
Results.....	131
Discussion.....	162
Conclusion.....	179
Recommendations.....	180
Summary.....	182
References.....	184
Arabic summary.....	

List of tables

Table (1) Genes and protein of the hepatitis B virus	26
Table (2) Life cycle of the hepatitis B virus.....	28
Table (3) Characteristic of HBV genotypes	37
Table (4) Advantages and disadvantages of different HBV genotyping methods	41
Table (5) Four phases of chronic HBV infection	73
Table (6) Factors affecting prognosis of chronic hepatitis B and compensated cirrhosis	74
Table (7) Interpretation of serological markers according to symptoms, transaminases and histological features	86
Table (8) Histological activity index.....	93
Table (9) Modified HAI grading: necroinflammatory scores.....	95
Table (10) Modified staging: architectural changes, fibrosis and cirrhosis....	96
Table (11) A glossary of definitions	97
Table (12) Comparison of three approved treatment of chronic hepatitis B...	119
Table (13) Recommendations for treatment of chronic hepatitis B	120
Table (14) Different categories in the excluded group	124
Table (15) Comparing age groups between the two study group.....	131
Table (16) Comparing demographic characteristics between the two studies groups.....	132
Table (17) Comparing different clinical presentations for patients between the studies groups	133
Table (18) Estimating the effect of some possible risk factors for HBV infection between the studies groups	134
Table (19) Frequency of risk factors for HBV infection in the studies groups.....	135
Table (20) Comparing age and some liver function parameters between the study groups	136

Table (21) Some liver function parameters in the studies groups.....	137
Table (22) Comparing some blood parameters between the study groups.....	138
Table (23) Comparing Hepatitis B seromarkers between the two study groups.....	139
Table (24) Comparing ultrasonographic findings of liver and spleen between the study groups	140
Table (25) Comparing liver biopsy findings between study groups.....	141
Table (26) Blood parameters and some liver function parameters in relation to the HBeAg among case group	142
Table (27) Relation between age groups and liver biopsy findings among the HBV DNA +ve group	143
Table (28) Relation between age distribution of patients in the HBV DNA +ve Genotype D patients and HAI biopsy results.....	144
Table (29) Demographic characteristics of patients in the HBV DNA +ve Genotype D patients and HAI biopsy results.....	145
Table (30) Relation between different clinical presentations of the HBV DNA +ve Genotype D patients and HAI biopsy results	146
Table (31) Relation between risk factors for HBV infection in the HBV DNA +ve Genotype D patients and HAI biopsy results	147
Table (32) Age and some liver function parameters of the HBV DNA +ve Genotype D patients and HAI biopsy results	148
Table (33) Some liver function parameters of patients in the HBV DNA +ve Genotype D patients and HAI biopsy results	149
Table (34) Some blood parameters of patients in the HBV DNA +ve Genotype D patients and HAI biopsy results	150
Table (35) Hepatitis B seromarkers of patients in the HBV DNA +ve Genotype D patients and HAI biopsy results	151
Table (36) Ultrasonographic findings of liver and spleen of the HBV DNA +ve Genotype D patients and HAI biopsy results	152
Table (37) Relation between age distribution of HBV DNA -ve patients and HAI biopsy results	153

Table (38) Demographic characteristics of HBV DNA -ve patients and HAI biopsy results	154
Table (39) Relation between different clinical presentations of HBV DNA -ve patients and HAI biopsy results	155
Table (40) Relation between risk factors for HBV infection of HBV DNA -ve patients and HAI biopsy results	156
Table (41) Age and some liver function parameters of HBV DNA -ve patients and HAI biopsy results	157
Table (42) Some liver function parameters of HBV DNA -ve patients and HAI biopsy results	158
Table (43) Some blood parameters of HBV DNA -ve patients and HAI biopsy results	159
Table (44) Hepatitis B seromarkers of HBV DNA -ve patients and HAI biopsy results	160
Table (45) Ultrasonographic findings of liver and spleen of HBV DNA -ve patients and HAI biopsy results	161

List of figures

Figure (1) Worldwide prevalence of HBV.....	8
Figure (2) Electron micrograph of hepatitis B virus in plasma (left) and budding of virus particles from hepatocytes	19
Figure (3) HBV genome organization and regulatory elements of orthohepadnaviruses	21
Figure (4) Structure of hepatitis B viral polymerase	23
Figure (5) Structure of hepatitis B viral HBc and HBe antigens and the C-gene from which they are derived	24
Figure (6) Life cycle of HBV.....	29
Figure (7) Dendrogram of HBV genotypes	34
Figure (8) Geographic distribution of HBV genotypes worldwide.....	36
Figure (9) LIPA HBV genotyping of (a) genotype A, (b) genotype B, (c) genotype C, and (d) genotype	40
Figure (10) Cumulative rates of spontaneous HBeAg seroconversion in Chinese patient with genotype B versus genotype C	43
Figure (11) Japanese patients with HCC stratified by age according to presence of genotype B versus genotype C	44
Figure (12) Distribution of liver disease among Japanese patients with genotype B versus genotype C	45
Figure (13) Increase risk of developing HCC among patients with genotype C versus genotype B	46
Figure (14) Cumulative probability of developing concurrent sustained biochemical remission DNA clearance in Spanish patients with genotype A versus genotype D	48
Figure (15) Response to IFN alpha therapy in Chinese patients with genotype B versus genotype C	52
Figure (16) Proportion of patients with HBeAg loss during Peg IFN alpha-2b therapy according to HBV genotype	54
Figure (17) Natural course of HBV infection	72
Figure (18) Incidence (cases per 100,000 per year) of hepatocellular carcinoma	

according to the stage of liver disease in patients with hepatitis B	76
Figure (19) Landmarks in hepatitis B.....	98
Figure (20) Action of IFN	100
Figure (21) Structure of Adefovir Dipivoxil	105
Figure (22) Structure of some antiviral drugs	106
Figure (23) Distribution of patients according to their HBsAg status	122
Figure (24) Recruitment of patients according to different inclusion/exclusion criteria	129

List of Abbreviations

AIDS	Acquired Immune Deficiency Syndrome
BP	Barber Protein
°C	Degree Centigrade
CCP	Critical control point
CAST	Council for Agriculture Science and Technology
CDC	Centers for Disease Control & Prevention
CFU	Colony Forming Unit
CMIR	Cell Mediated Immune Response
CT	Cholera Toxin
E coli	Escheretia coli
EIA	Enzyme Immuno-Assay
ELISA	Enzyme Linked Immune Sorbent Assay
FAO	Food and Agriculture Organization
FDA	Food and Drug Administration
GIT	Gastro-Intestinal Tract
HACCP	Hazard analysis critical control point
Ig A	Immunoglobulin A
Ig G	Immunoglobulin G
Ig M	Immunoglobulin M
LIS	Lysine Iron Sugar
LMI	Lymphocyte Migration Inhibition
LPS	Lipopolysaccharide
LT	Heat Labile enterotoxin
2-ME	2-mercaptoethanol
MIO	Motility Indole Ornithine
NTS	Non Typhoidal Salmonella
OMPS	Outer membrane proteins
OR	Odds Ratio
S Ig A	Salmonella Immunoglobulin A
TAB	typhi, paratyphi A & paratyphi B
TSI	Triple Sugar Iron agar
UK	United Kingdom
Vi	Virulence
VICPS	Vi Capsular Polysaccharide Vaccine
WHO	World Health Organization
WTA	World Trade Organization

List of Abbreviations

ADCC	Antibody Mediated Cellular Cytotoxicity
ADV	Adefovir Dipivoxil
AHF	Acute hepatic Failure
ALT	Alanine Aminotransferase
AST	Aspartate Amino transferase
AVH	Acute Viral Hepatitis
BCP	Basal Core promoter Mutations
cccDNA	Covalantly Closed Circular DNA
CHB	Chronic Hepatitis B
CTL	Cytotoxic T Lymphocytes
DNA	Deoxy Ribonucleic Acid
DNA Pol	DNA Polymerase
EASL	European Association for the Study of the Liver
ELISA	Enzyme Linked Immunosorbent Assays
HBcAb	Hepatitis B core Antibody
HBcAb Igm	Hepatitis B antibody Immunoglobulin M
HBsAg,Ab	Hepatitis B e antigen and antibody
HBIG	Hepatitis B Immunoglobulines
HBsAb	Hepatitis B surface Antibody
HBsAg	Hepatitis B surface Antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HCW	Health Care workers
HIV	Human Immunodeficiency Virus
HLA	Human Leucocyte Antigen
IFN Alpha	Interferon Alpha
IVUD	Intravenous drug users
Line probe Assay	Line Probe Assay
NHTMRI	National Hepatol. Trop. Med. Research Institute
NIH	National Institute of Health
NK	Natural Killer Cells
OLT	Orthotopic Liver Transplantation
PCR	Polymerase Chain Reaction
Peg IFN Alpha	Pegylated Interferon Alpha
RFLP	Restriction Fragment Length Polymorphism
TNF	Tumour Necrosis Factor
WHO	World Health Organization

Introduction

Since its first description more than 30 years ago, infection with hepatitis B virus (HBV) has been recognized as a major cause of chronic liver disease, liver cirrhosis and hepatocellular carcinoma world wide, with peak prevalence in the Far East and African regions.(*Zoulim. 2004*)

Despite the development and use of highly protective HBV vaccines in the last two decades, still the WHO estimates that over 2 billions of the world population have been infected with HBV and between 350- 400 million individuals are currently chronic carriers of the virus, with at least 1 million deaths occurring annually as a direct consequence of the infection.(*Maddery et al ., 2001*)

HBV belongs to the hepadnaviridae family, a tiny extraordinary DNA virus that posses the smallest genome of all human viruses (*Wang et al., 2002*)

Mode of transmission of the disease is mainly parenteral through contaminated unscreened blood transfusion and often by intimate sexual contact (*Mc Mahon et al., 2001*). Passage of the virus from an infected mother ,the so called vertical transmission, also plays a role in wide-spreading HBV. The chance increases in acute rather than chronic carrier-mothers. (*Chang, 2000*). Dialysis machines, dental procedures, and unsterile surgical instruments are important routes of HBV transmission.(*Wang et al., 2002*).

Clinically the disease could present as either acute or chronic hepatitis. Acute hepatitis B usually presents by an increase in ALT and AST levels and is defined by detectable HBsAg, HBcAb (Igm)or both.(*Decker.1998*). Duration of the disease is variable, and improvement

could be monitored by seroconversion of HBeAg to HBeAb and complete cure by seroconversion of HBsAg to HBsAb (*Furusyo et al., 1999*). Complete clinical recovery occurs in 90 – 95 % of the horizontally transmitted cases, unlike vertically transmitted ones that retain the infection and become chronic in 70 -80 % of cases (*Furusyo et al., 1999*).

Chronic infection is characterized by the persistence of serum HBsAg and HBcAb. HBV DNA may remain detectable in serum or liver using polymerase chain reaction (PCR) based tests following the disappearance of HBsAg in serum, the clinical significance of the persistence of very low levels of HBV DNA is still controversial (*Brechot et al., 2001*).

Approximately 10% of adults and about 90% of neonates contracting HBV will not clear the HBsAg from serum within 6 months and become chronic carriers (*McMahon et al., 2001*) they mostly have normal liver profile and on the level of liver biopsy may present by non specific minimal abnormalities through to chronic hepatitis and cirrhosis (*Thursz, 2001*).

However the clinical course that HBV leads is quite variable, from completely asymptomatic disease through to mild constitutional manifestations and, finally complications as liver cell failure, ascites, esophageal varices, encephalopathy and / or hepatocellular carcinoma (*Thakur et al., 2002*), which suggests the presence of certain viral factors behind those variations.

The recent application of molecular technology for gene amplification and sequencing to the study of these viruses, especially those that cause persistent infections, has unraveled their significant heterogenicity and their potential for rapid evolution (*Esteban, 1999*).

Based on an 8% nucleotide divergence of HBV genome, HBV is classified into seven genotypes: A to G which tend to be distributed geographically. (*Norder et al., 1992*) and (*Stuyver et al., 2000*). An eighth genotype, designated H, was reported from Central America (*Arauz-Ruiz et al., 2002*). Four fundamental antigenic subtypes and five other subtypes are antigenically defined, based on amino acid substitutions in the S protein (*Kato et al., 2001*)

The clinicopathological outcome of the disease was found to be closely related to the subtype backbone (*Chan et al., 2002*)a.

Genotype A was found to be associated with less severe liver disease than genotype D. Moreover, genotype D was also more prevalent than genotype A among patients with Child-Pugh B or C cirrhosis. (*Thakur et al., 2002*).

. In addition, genotype B was found to be associated with severe icteric flares (*Chan et al., 2002*)b.

Nevertheless, HBV genotypes may be related to the development of HCC (*Kao et al., 2000*)b and may also affect the response of patients to lamivudine therapy either in chronic HBV cases or after liver transplantation (*Ben Ari et al., 2003*).